Treatment options in type-2 low asthma
Monoclonal antibodies targeting IgE or the type-2 cytokines IL-4, IL-5 and IL-13 are proving highly effective in reducing exacerbations and symptoms in people with severe allergic and eosinophilic asthma respectively. However, these therapies are not appropriate for 30–50% of patients in severe asth...
Главные авторы: | Hinks, TSC, Levine, SJ, Brusselle, GG |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
European Respiratory Society
2020
|
Схожие документы
-
FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
по: Couillard, S, и др.
Опубликовано: (2021) -
Non-typeable Haemophilus influenzae airways infection: the next treatable trait in asthma?
по: Hinks, TSC, и др.
Опубликовано: (2022) -
Boosting MAIT cells as immunotherapy: Context is everything
по: Hinks, TSC
Опубликовано: (2020) -
Azithromycin for mild-to-moderate COVID-19 - Authors' reply
по: Hinks, TSC
Опубликовано: (2021) -
A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
по: Couillard, S, и др.
Опубликовано: (2021)